drugset
drugset / Trial / NCT02534467

Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?

NCT02534467 ↗

Phase 4 Completed 60 enrolled Murdoch Childrens Research Institute Monash University · collab
RandomizedCrossoverSingle-blindTreatment

Summary

An open-label (outcome assessor blinded) prospective crossover cohort study of children 6-16 years assessing effects of Montelukast on moderate to severe atopic dermatitis.

Timeline

Start
2015-07-09
Primary completion
2018-12-04
Completion
2018-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Montelukast Other / unclassified 4 mg Oral
Subject Montelukast Other / unclassified 5 mg Oral
Subject Montelukast Other / unclassified 10 mg Oral

Indications

atopic eczema